Vaginal medical device effective against infections and vaginal dryness
Vulvovaginal infections caused by Candida albicans are one of the leading causes of female intimate discomfort, with recurring symptoms such as itching, burning, leucorrhoea and pain during intercourse. They affect women of all ages and can occur even in the absence of obvious risk factors. They are often accompanied by conditions such as vaginal dryness and changes in pH and bacterial flora, which worsen the clinical picture and have a profound impact on quality of life.
To address these issues effectively and safely, Gruppo FarmaImpresa has developed Lattawin Gel, a topical vaginal medical device (FT.CE.113) whose efficacy has been confirmed by two independent clinical studies, with particular focus on reducing the presence of Candida and improving subjective symptoms.
Clinical study: Lattawin Gel reduces positive swab results for Candida
In the first clinical study, 30 women with symptoms of vaginal candidiasis were treated with Lattawin Gel for 4 weeks. Treatment efficacy was assessed both through clinical symptoms (Total Symptoms Score – TSS) and by vaginal swab test to detect the presence of Candida albicans.
The results showed that swab positivity dropped from 100% to 3.6%, with extremely high statistical significance (p < 0.0001). At the same time, the TSS score fell from 7.9 to 0.56, showing marked improvements in symptoms such as burning, dysuria, leucorrhoea and dyspareunia.
In addition to symptomatic and microbiological remission, patients reported a clear improvement in their quality of life, measured with the PCS-12 and MCS-12 questionnaires, with significant improvements in both the physical (p = 0.00016) and mental (p = 0.0013) components.
Lattawin Gel and vaginal dryness: results from the VSQ study
In parallel, a second observational clinical study evaluated the efficacy of Lattawin Gel in treating vulvovaginal dryness in a sample of 20 women. The reference parameter was the Vulvovaginal Symptoms Questionnaire (VSQ), a validated tool for assessing subjective symptoms, emotional impact and quality of sexual life.
After 4 weeks of treatment, the mean VSQ score decreased from 4.10 to 0.15 points, with a mean improvement of 4.05 (p < 0.001). 95% of patients achieved complete remission of symptoms, and all showed significant progress in itching, dryness, changes in vaginal discharge and odour. Aspects related to sexual and emotional life also benefited from the treatment.
Who is Lattawin Gel for?
Lattawin Gel is indicated for the following conditions:
- Vulvovaginal candidiasis, including recurrent forms
- Vaginal dryness due to menopause, breastfeeding, stress or medication
- Intimate irritation with burning, itching or post-coital discomfort
- Imbalances in the vaginal microbiota and pH
- Discomfort during sexual intercourse
The product is suitable for women of childbearing age, in menopause or postpartum, and can also be used to support conventional antifungal treatments.
Why choose Lattawin Gel?
Lattawin Gel is a medical device with clinically proven efficacy in two independent studies conducted by Gruppo FarmaImpresa. The results show:
- A 96% reduction in swab positivity for Candida
- Symptom remission in 95% of vaginal dryness cases
- Significant improvement in intimate and sexual quality of life
Lattawin Gel is ready for your business
If you are a company in the healthcare, gynaecology or pharmaceutical distribution sector, Lattawin Gel is a concrete opportunity to expand your portfolio.
The device is available ready to market or as private label, with full support for customisation, registration and international distribution.
